Earnings ·
enGene Therapeutics Inc. reported financial results for the third quarter ended July 31, 2026, posting a net loss of…
ENGNenGene Therapeutics Inc.
enGene Therapeutics Inc. reported financial results for the third quarter ended July 31, 2026, posting a net loss of $32.5 million, or $0.47 per share, compared to $29.0 million in the prior year period. Total operating expenses rose to $34.0 million from $29.9 million, driven by increased general and administrative costs related to workforce reductions and personnel annualization, partially offset by lower research and development spending. The company ended the quarter with $266.3 million in cash, cash equivalents, and marketable securities. Clinically, enGene cleared a safety run-in for a surfactant plus detalimogene cohort and plans to report updated regulatory endpoint data from its pivotal LEGEND trial in the fourth quarter of 2026. The company also anticipates initiating a Biologics License Application (BLA) submission before year-end and holding a pre-BLA meeting with the FDA during that period. enGene Therapeutics Inc. is a clinical-stage biotechnology company developing non-viral genetic medicines for mucosal tissues, specifically targeting non-muscle invasive bladder cancer.